Evaluation of carry-over, product quality and cleaning validation following a batch campaign manufacturing of benzydamine hydrochloride spray 0.15%
Elena Petrovska Kostadinoska1✉, Irena Slaveska Spirevska1, Katerina Kochova1, Kristina Grncaroska1, Silvana Janevikj1, Jana Micevska1, Milena Prculovska1
- 1 Replek Farm, Skopje, Str. Kozle 188 Skopje, Republic of North Macedonia
Received 3 November 2026 · Accepted 14 November 2026 · Published 14 November 2026
Article PDF · Original poster (PDF)
- view
- 1
- download
- 1
- countries
- 2
Since publication · journal site · robots excluded
Abstract
Introduction
Campaign manufacturing reduces equipment downtime, water and cleaning-agent use, and production cost but must be scientifically justified to protect product quality and patient safety under EU GMP. Consecutive same-product batches remove cross-contamination risk between different APIs, yet residue build-up, degradation in poorly drained areas, and microbial proliferation remain relevant quality risks. Benzydamine hydrochloride is a topical NSAID with analgesic and anti-inflammatory action, used for inflammatory conditions of the oral cavity and pharynx.
Materials and methods
Ten consecutive commercial-scale batches were produced using the same equipment and approved manufacturing process without intermediate cleaning or sanitization, only standardized drain-down and line-clearance after every batch. A full automated CIP cycle was executed only after completion of batch 10. Risk-based swab sampling targeted highest residue-retention potential locations. Validated, stability-indicating RP-HPLC with UV detection at 232 nm was used for analysis. MACO derivation was based on toxicology data applying LOEL/LOAEL approach and PDE calculations.
Results
Method validation showed high specificity, linearity, and precision suitable for monitoring trace-level benzydamine residues. Residue levels stayed below the calculated MACO with no cumulative build-up across the campaign. Standardized drain-down and line-clearance were effective after each batch. Full CIP cycle was only needed after batch 10, followed by cleaning validation swabbing confirming restoration of a validated clean state.
Conclusion
Ten consecutive batches of benzydamine HCl spray 0.15% can be manufactured without intermediate cleaning while maintaining product quality, microbiological control and GMP compliance. Residues stayed below MACO with no cumulative build-up. Post-campaign CIP cleaning validation confirmed full restoration of a validated clean state. Findings provide scientific justification for a 10-batch campaign manufacturing strategy.
Original poster
References
- European Commission, 2015. EudraLex – Volume 4: EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Annex 15: Qualification and Validation.; European Medicine Agency (EMA), 2014. Guideline on setting health-based exposure limits for use in risk identification in the manufacture of different medicinal products in healthcare facilities, EMA/CHMP/CVMP/SWP/169430/2012.; National Center for Biotechnology Information, 2026. PubChem Compound summary for CID 65464, Benzydamine hydrochloride. Retrieved: June 10, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/Benzydamine-Hydrochloride; Tox by design, 2024. PDE Monograph for Benzydamine Hydrochloride, Oromucosal route, October, Division of Socosur Chem, 54 Rue de Londres, Paris France.
Related posters
Pharmaceutical IndustryDevelopment and optimization of an in vitro dissolution method for metronidazole and clotrimazole vaginal pessariesK. Grncharoska, I. Slaveska Spirevska, T. Bakovska Stoimenova and 4 others
Pharmaceutical IndustrySetting cleaning validation acceptance limits and developing an HPLC method for determination of risperidone residues on manufacturing equipmentM. Prculovska, K. Kochova, I. Slaveska Spirevska and 3 others
Pharmaceutical IndustryNew perspectives in the drug treatment of auditory and vestibular analyzer disordersS. Parii, L. Uncu, A. Ungureanu and 2 others
Pharmaceutical IndustryEuropean pharmaceutical legislation reform: Overview and implications for innovation, access and public healthL. Ivceska